Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
CPT: Pharmacometrics & Systems Pharmacology
|
June 4, 2021
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients
Stefan Willmann, Eleonora Marostica, Nelleke Snelder, et al.
Kidney International
|
March 27, 2024
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis
Wolfgang C Winkelmayer, Anthonie W A Lensing, Ravi I Thadhani, et al.
Journal of Clinical Pharmacology
|
September 15, 2021
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study
Peijuan Zhu, Stefan Willmann, Wangda Zhou, et al.
Blood Advances
|
August 25, 2022
Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
Joseph S Palumbo, Anthonie W A Lensing, Leonardo R Brandão, et al.
Frontiers in Physiology
|
April 13, 2011
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks
Thomas Eissing, Lars Kuepfer, Corina Becker, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
August 22, 2021
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis
Nico Derichs, Jennifer L Taylor-Cousar, Jane C Davies, et al.
Pulmonary Circulation
|
October 3, 2022
Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study
Humberto García Aguilar, Matthias Gorenflo, D Dunbar Ivy, et al.
The Lancet. Haematology
|
August 18, 2019
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
Paul Monagle, Anthonie W A Lensing, Kirstin Thelen, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 19, 2025
Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges
James W T Yates, Michael Zientek, Kunal S Taskar, et al.
Journal of Thrombosis and Haemostasis : JTH
|
April 5, 2020
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation
Guy Young, Anthonie W A Lensing, Paul Monagle, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
CPT: Pharmacometrics & Systems Pharmacology
|
June 4, 2021
PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients
Stefan Willmann, Eleonora Marostica, Nelleke Snelder, et al.
Kidney International
|
March 27, 2024
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis
Wolfgang C Winkelmayer, Anthonie W A Lensing, Ravi I Thadhani, et al.
Journal of Clinical Pharmacology
|
September 15, 2021
Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study
Peijuan Zhu, Stefan Willmann, Wangda Zhou, et al.
Blood Advances
|
August 25, 2022
Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
Joseph S Palumbo, Anthonie W A Lensing, Leonardo R Brandão, et al.
Frontiers in Physiology
|
April 13, 2011
A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks
Thomas Eissing, Lars Kuepfer, Corina Becker, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|
August 22, 2021
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis
Nico Derichs, Jennifer L Taylor-Cousar, Jane C Davies, et al.
Pulmonary Circulation
|
October 3, 2022
Riociguat in children with pulmonary arterial hypertension: The PATENT-CHILD study
Humberto García Aguilar, Matthias Gorenflo, D Dunbar Ivy, et al.
The Lancet. Haematology
|
August 18, 2019
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
Paul Monagle, Anthonie W A Lensing, Kirstin Thelen, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
November 19, 2025
Physiologically-Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges
James W T Yates, Michael Zientek, Kunal S Taskar, et al.
Journal of Thrombosis and Haemostasis : JTH
|
April 5, 2020
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation
Guy Young, Anthonie W A Lensing, Paul Monagle, et al.
Page
of 8